Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CER-001
- Development stage
- Phase 3
- Lead developer
- ABIONYX Pharma
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CER-001 is a recombinant high-density lipoprotein (HDL) mimetic designed to replicate the structure and function of nascent (pre-beta) HDL. It consists of human recombinant apolipoprotein A-I (ApoA1), the main protein component of natural HDL, combined with two phospholipids—sphingomyelin and dipalmitoyl-phosphatidylglycerol. The drug acts by stimulating cholesterol efflux from macrophages and promoting reverse lipid transport (reverse cholesterol transport), thereby capturing excess cholesterol and facilitating its elimination from the body. This mechanism is intended to address conditions characterized by low HDL or dysfunctional lipid metabolism. CER-001 has orphan drug status for lecithin-cholesterol acyltransferase deficiency and hypoalphalipoproteinaemia, and it has been investigated in clinical trials for acute coronary syndrome, acute kidney injury, atherosclerosis, uveitis, as well as being considered for hyperinflammatory states such as those seen in COVID-19[1][2][3][4][6].
- Brand names
- Cerenis HDL
- Other names
- Recombinant human apolipoprotein A-I/phospholipid complexRecombinant Human Apolipoprotein A-IRecombinant Human Apolipoprotein A-I/Phospholipids complex
02
Targets
ABCA1 (ATP-binding cassette transporter A1)LCAT (Lecithin-cholesterol acyltransferase)APOA1 (Apolipoprotein A-I)
Beyond the preview
Go deeper on CER-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CER-001.